Marked up Amended Claims

4. (Amended) An immunotherapeutic agent of claim[s] 1, [2 and 3] wherein the cell lines derived from normal tissue [are chosen from from] and are selected from the group consisting of PNT1A (ECACC Ref No: 95012614) [or] and PNT2 (ECACC Ref No: 95012613).

5. (Amended) An immunotherapeutic agent of claim[s] 1, [2 and 3] wherein the cell line[(]s[)] derived from tumor tissue [is/are chosen from] and are selected from the group consisting of NIH1519-CPTX, NIH1532-CP2TX, NIH1535-CP1TX, NIH1542-CP3TX, CA-HPV-10, LnCap, DU145 [or] and PC3.

9. (Amended) An immunotherapeutic agent of claim[s] $1_{,}$[-8] wherein the tumor cell lines have been irradiated at 50 to 300 Gy.

10. (Amended) An immunotherapeutic agent of claim[s] $1_{,}$[-8] wherein the tumor cell lines have been irradiated at 100 to 150 Gy.

11. (Amended) An allogeneic immunogenic composition comprising an immunotherapeutic agent of claim[s] 1[-10] combined with a vaccine adjuvant selected from [mycobacterial preparations such as] the group of consisting of $BCG_{,}$ [or] *M. Vaccae*, Tetanus toxoid, Diphtheria toxoid, *Bordetella Pertussis*, interleukin 2, interleukin 12, interleukin 4,

interleukin 7, Complete Freund's Adjuvant, Incomplete Freund's Adjuvant [or other], and non-specific [agents] adjuvant.

12. (Amended) An immunogenic composition comprising an immunotherapeutic agent of claim[s] 1[-10] combined with a vaccine adjuvant [selected from], wherein the adjuvant is a mycobacterial preparation[s such as BCG or *M. Vaccae]*.

13. (Amended) An immunotherapeutic agent [or composition] of claim[s] 1,[-12] wherein the cells are formulated with a cryoprotectant solution [including but not limited to] comprising at least one selected from the group 10-30% v/v aqueous glycerol solution, 5-20% v/v dimethyl sulphoxide [or] and 5-20% w/v human serum albumin[either as single cryoprotectants or in combination].

14. (Amended) An immunotherapeutic agent [or composition] of claim[s] 1,[-12] wherein the cells are formulated with a cryoprotectant solution [including] comprising 5-20% v/v dimethyl sulphoxide and 5-20% w/v human serum albumin [in combination].

15. (Amended) An immunotherapeutic agent [or composition] of claim[s] 1[-14], wherein said agent [that] induces an immune response in patients characterized by activation of immune T-cells.

16. (Amended) An immunotherapeutic agent [or composition] of claim[s] 1[-14], wherein said agent [that] induces an immune response in patients characterized by induction of antibody production.

17. (Amended) An immunotherapeutic agent [or composition] of claim[s] 1[-14], wherein said agent [that] induces a decrease in the rate of rise or a decline in the level of serum PSA in prostate cancer patients.

18. (Amended) An immunotherapeutic agent [or composition] according to claim[s] 1[-17], wherein said agent [that] is administered intradermally.

19. (Amended) An immunotherapeutic agent [or composition] according to claim[s] 1[-17], wherein said agent [that] is administered intra-prostatically.

20. (Amended) An allogeneic immunotherapeutic vaccine composition for the treatment of prostate cancer, [which] wherein said composition comprises [or consists of] an agent according to [any preceding] claim 1 [together with] and a physiologically acceptable agent selected from the group consisting of an excipient, an adjuvant [or] and a carrier.

21. (Amended) An allogeneic method of prophylaxis or treatment of prostate cancer[, which includes] by administering to a patient an effective amount of agent [or composition] according to [any preceding] claim 1 [in one or more doses in suitable dosage form].

22. (Amended) An allogeneic method of using [Use of] an agent according to [any of] claim[s] 1 [to 10] in the manufactur[e]ing of a medicament for the allogeneic treatment of human prostate cancer.